Clinical Scorecard: Low-Dose Rivaroxaban Did Not Reduce LV Thrombus After Anterior STEMI
At a Glance
| Category | Detail |
|---|---|
| Condition | Anterior ST-segment elevation myocardial infarction (STEMI) |
| Key Mechanisms | Assessment of left ventricular thrombus formation |
| Target Population | Adults with anterior STEMI and anterior wall motion abnormalities |
| Care Setting | Multicenter clinical trial |
Key Highlights
- Low-dose rivaroxaban did not significantly reduce left ventricular thrombus compared to dual antiplatelet therapy alone.
- Left ventricular thrombus detected in 14% of rivaroxaban group vs. 17% in dual therapy group.
- Major adverse cardiovascular events were uncommon and similar across groups.
- Bleeding events were more frequent in the rivaroxaban group (18% vs. 9%).
- Exploratory analyses suggested lower thrombus rates with ticagrelor-based regimens.
Guideline-Based Recommendations
Diagnosis
- Cardiac magnetic resonance imaging to assess left ventricular thrombus.
Management
- Dual antiplatelet therapy with aspirin and either clopidogrel or ticagrelor.
Monitoring & Follow-up
- Monitor for bleeding events, especially in patients receiving triple therapy.
Risks
- Increased risk of minor bleeding with rivaroxaban.
Patient & Prescribing Data
560 patients with anterior STEMI treated at 29 centers in France.
Rivaroxaban (2.5 mg twice daily) added to dual antiplatelet therapy did not meet primary endpoint.
Clinical Best Practices
- Consider patient characteristics when prescribing antithrombotic regimens.
- Assess bleeding risk prior to initiating triple therapy.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
